Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Syed Khurram Mushtaq Gardezi Added: 3 years ago
Today, in cardiology, acute coronary syndrome (ACS) is one of the most common presentations in hospitals. Usually, the history and presenting features of ACS are very typical. However, some patients have an atypical presentation, which can pose a problem for prompt diagnosis and management, leading to an overall increase in morbidity and mortality in such patients. Case Presentation A 61-year… View more

Vascular Disease and Surgery

Imaging & Diagnostics
Ranil de Silva
Research Area(s) / Expertise:

Coronary Artery Disease and Myocardial Infarction

Coronary Interventions

 Job title: Senior Lecturer in Clinical Cardiology and Consultant Interventional Cardiologist
Dr Ranil de Silva is a Senior Lecturer in Clinical Cardiology and Consultant Interventional Cardiologist at the Royal Brompton Hospital, where he leads the Specialist Angina Service. Dr de Silva completed his training in general and interventional cardiology in London, including at the Royal Brompton, Hammersmith and St Mary’s Hospitals. He undertook post-doctoral research at the Division of… View more
The Perilousness of Antidepressant Drugs in a Real-world Cohort of Patients with Acute Coronary Syndrome
Author(s): A Denegri , L Raeber , S Windecker , et al Added: 3 years ago
Background: Although antidepressant therapy has been related to increased cardiovascular risk, depression, and its adverse effects on prognosis, is a well-recognised entity among acute coronary syndrome (ACS) patients. The aim of the study was to evaluate prevalence and outcome of antidepressant treatment in a real-world cohort of ACS patients. Methods: We sought to assess the prevalence of… View more

MI/ACS
The Relationship between Neutrophil to Lymphocyte Ratio with Rehospitalisation and Mortality in Patients with Acute Coronary Syndrome
Author(s): J Lesmana , A Lefi Added: 11 months ago

Vascular Disease and Surgery
ACC 24 Late-Breaker Discussion: The AEGIS-II Trial
Author(s): Harriette Van Spall , Michael C Gibson Added: 1 week ago
ACC 2024 — Late-breaker host, Dr Harriette Van Spall and Principal Investigator, Dr C Michael Gibson discuss the AEGIS-II trial (CSL Behring) (NCT03473223).This phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study investigated the efficacy and safety of an apolipoprotein A-I (apoA-I), CSL112 in patients with acute coronary syndrome (ACS). Investigators enrolled… View more

Prevention & Chronic Conditions

MI/ACS
ESC 23: The STOPDAPT-3 Study
Author(s): Masahiro Natsuaki Added: 7 months ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111). In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at… View more

MI/ACS

Intervention
STOPDAPT-2 ACT: 1-month DAPT Followed by Clopidogrel Monotherapy in ACS
Author(s): Hirotoshi Watanabe Added: 2 years ago
Dr. Hirotoshi Watanabe (Kyoto University Graduate School of Medicine, JP) discusses the results of the STOPDAPT-2 ACS study. The aim of this study was to assess the safety of reducing dual antiplatelet therapy (DAPT) duration to 1-month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS). The trial showed that in ACS… View more

Anticoagulation

Intervention
Prognostic Utility of the ABCD-GENE Score in Asian ACS Patients
Author(s): Cheng Keat Tan , David Bin-Chia Wu , Seh Yi Joseph Tan , et al Added: 5 months ago

Anticoagulation

MI/ACS
ESC 23: New Guidelines For the Management of Acute Coronary Syndromes
Author(s): Robert A Byrne Added: 7 months ago
ESC 2023 — Dr Robert Byrne (Mater Private Hospital, Dublin, IE) joins us on-site to discuss the new guidelines from the ESC covering the management of acute coronary syndromes. Acute Coronary Syndrome (ACS) is a broad spectrum of conditions, and the presentation can vary from a stable patient, to a patient who is critically ill. In the past, separate guidelines were issued for ST-Elevation… View more

Standards & Guidelines

MI/ACS
Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
Author(s): Nikita Lomakin , Anna Rudakova , Liudmila Buryachkovskaya , et al Added: 3 years ago
Antiplatelet agents are part of secondary prevention following acute coronary syndrome (ACS). Current European and Russian guidelines recommend dual antiplatelet therapy for 1 year after ACS.1,2 Prasugrel is not marketed in Russia, so high-risk patients have been given ticagrelor. The proportion of generic clopidogrel administered has been steadily rising, with the average cost of treatment… View more

Anticoagulation

MI/ACS